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Characterization of different 
fat depots in NAFLD using 
inflammation-associated 
proteome, lipidome and 
metabolome
Alen Lovric1, Marit Granér2, Elias Bjornson3,4, Muhammad Arif1, Rui Benfeitas1, 
Kristofer Nyman5, Marcus Ståhlman4, Markku O. Pentikäinen2, Jesper Lundbom5, 
Antti Hakkarainen  5, Reijo Sirén  6, Markku S. Nieminen2, Nina Lundbom5, Kirsi Lauerma5, 
Marja-Riitta Taskinen2, Adil Mardinoglu1,3 & Jan Boren  4
Non-alcoholic fatty liver disease (NAFLD) is recognized as a liver manifestation of metabolic 
syndrome, accompanied with excessive fat accumulation in the liver and other vital organs. Ectopic 
fat accumulation was previously associated with negative effects at the systemic and local level in 
the human body. Thus, we aimed to identify and assess the predictive capability of novel potential 
metabolic biomarkers for ectopic fat depots in non-diabetic men with NAFLD, using the inflammation-
associated proteome, lipidome and metabolome. Myocardial and hepatic triglycerides were measured 
with magnetic spectroscopy while function of left ventricle, pericardial and epicardial fat, subcutaneous 
and visceral adipose tissue were measured with magnetic resonance imaging. Measured ectopic fat 
depots were profiled and predicted using a Random Forest algorithm, and by estimating the Area Under 
the Receiver Operating Characteristic curves. We have identified distinct metabolic signatures of fat 
depots in the liver (TAG50:1, glutamate, diSM18:0 and CE20:3), pericardium (N-palmitoyl-sphinganine, 
HGF, diSM18:0, glutamate, and TNFSF14), epicardium (sphingomyelin, CE20:3, PC38:3 and TNFSF14), 
and myocardium (CE20:3, LAPTGF-β1, glutamate and glucose). Our analyses highlighted non-invasive 
biomarkers that accurately predict ectopic fat depots, and reflect their distinct metabolic signatures in 
subjects with NAFLD.
NAFLD is recognized as the most prevalent liver disorder in Western countries, predicted to become the major 
cause for liver transplantation in the near future1. NAFLD encompasses the spectrum of chronic liver disorders 
ranging from asymptomatic non-alcoholic steatosis, defined by liver enlargement and abnormal accumulation 
of lipids without inflammation, to NASH, a more clinically significant form of NAFLD. The latter is character-
ized by hepatic inflammation and fibrosis that can eventually lead to cirrhosis and hepatocellular carcinoma1,2. 
NAFLD is also linked to metabolic syndrome (MetS), a cluster of risk factors including central obesity, high blood 
pressure, elevated level of fasting plasma glucose, high serum triglycerides (TGs) and low levels of high-density 
lipoproteins (HDL). These complications are also well known causative factors of insulin resistance (IR), type 2 
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diabetes (T2D) and cardiovascular disease (CVD)3–5. The association between NAFLD and CVD is of particular 
interest as numerous studies pointed out to an increased prevalence of heart related conditions among NAFLD 
patients6,7. Specifically, under liver steatosis, the cardiovascular system is compromised, exhibiting structural 
alterations and remodeling8. For example, animal studies have shown that intracellular lipid accumulation in 
the myocardium and other toxic products of fatty acid (FA) metabolism causes cardiac lipotoxicity, impairs left 
ventricular (LV) function, and promotes cardiac fibrosis and apoptosis9. Myocardial TG content is higher in sub-
jects with obesity10, MetS11, impaired glucose tolerance12 or T2D13,14, suggesting that cardiac steatosis is relatively 
common in humans. Importantly, these increases in intramyocardial TG levels precede the development of car-
diac dysfunction, suggesting a causative role of myocardial fat in the development of obesity/glucose intolerance/
T2D-induced cardiac dysfunction14,15.
It has been reported that cardiac fat accumulation contributes to the high mortality following myocardial 
infarction in subjects with T2D16. However, despite an increasing body of evidence showing an association 
between elevated myocardial TG content and cardiac dysfunction in humans17, it remains largely unclear whether 
and how alterations in myocardial TG synthesis and hydrolysis affect heart function. In fact, we have previously 
shown that in obese, non-diabetic men only accumulation of epicardial and pericardial, but not of myocardial 
TG, was linked to the severity of structural and functional alterations of the heart18. Although myocardial TG 
content is recognized as a site of ectopic fat accumulation, it may be regulated by other factors than those linked 
to systemic fat depositions.
Over the past decade new technologies that embrace the term –omics have evolved to address increasingly 
complex biological questions arising out of the postgenomic era. Analysis of small metabolites and lipids is 
expected to provide many more additional insights and clues to the mechanisms of biological processes and func-
tions, and thus may increase our knowledge of the development and progression of CVD. Here, we determined 
the independent role of a broad panel of parameters comprising plasma proteins associated with inflammation as 
well as plasma lipid (lipidome) and metabolite (metabolome) signatures in the occurrence of myocardial, epicar-
dial, pericardial and liver fat among male subjects with NAFLD.
Results
Association of clinical parameters with various fat depots. Ectopic fat (myocardial, epicardial, per-
icardial and liver) was measured in non-diabetic male subjects with NAFLD, which were split into high and low 
fat groups. Clinical and biochemical features of the subjects are summarized in Supplementary Table 1. Subjects 
with high level of ectopic fat tended to present characteristics of MetS (myocardial: 72% subjects; epicardial: 
76%; pericardial: 88%: liver: 92%), and were overall older with increased BMI, waist circumference, IR and more 
pronounced smoking habits compared to subjects with low level of ectopic fat. Serum level of TG, total choles-
terol, low density lipoprotein (LDL), very low density lipoprotein, apolipoprotein B (apoB) were also significantly 
increased in subjects with high level of ectopic fat. In turn, the levels of HDL tend to be lower with increasing 
levels of measured ectopic fat. HOMA-index, plasma glucose and insulin levels, as well as their levels after first 
and second hour during OGTT, were higher among subjects with high level of ectopic fat.
Serum concentrations of potential biomarkers for cardiac fat depots (beta-hydroxybutyrate (β-OHB), fatty 
acid binding protein (AFABP), leptin and adiponectin) previously proposed by (Graner et al. 2015) demonstrated 
similar behaviour across the measured ectopic fat depots. For instance, AFABP and leptin were significantly 
higher among subjects with high ectopic fat, whereas adiponectin levels were significantly lower, compared to 
subjects with low ectopic fat depots. β-OHB levels were found to be significantly lower among individuals with 
high levels of myocardial and epicardial fat (Supplementary Table 1).
We have performed an association analysis (Fig. 1) and observed that visceral and subcutaneous fat, waist 
circumference, BMI, AFABP, HOMA-index, leptin, fasting glucose and insulin, TG levels, systolic and diastolic 
blood pressures were positively correlated with the levels of measured fat depots whereas adiponectin, HDL and 
β-OHB showed negative correlations. Furthermore, negative correlations were observed between LV early dias-
tole, peak filing rate (PFR), LV end-diastolic volume (LVEDV), PFR/LVEDV and high levels of measured ectopic 
fat. Our association analysis also showed that among ectopic fat depots around the heart, pericardial fat showed 
the strongest correlation with the clinical status of subjects involved in this study, significantly correlating with 
majority of the clinical parameters analysed.
Relationship of inflammation-associated proteome and various fat depots. In order to under-
stand the link between measured ectopic fat and inflammation, we quantified a range of biomarkers associated 
with inflammation. We used a multiplex immunoassay enabling analysis of 92 inflammation-related protein bio-
markers. The relationship between these biomarkers and measured ectopic fat depots are presented in Fig. 2. We 
observed that pericardial fat displayed the highest correlation with inflammation-related proteins whose levels 
significantly differed between subjects with high and low ectopic fat.
Based on our analysis, pericardial fat showed significant positive correlation with several growth factor pro-
teins including hepatocyte growth factor (HGF), vascular endothelial growth factor A (VEGF-A), fibroblast 
growth factors 21 and 23 (FGF21 and FGF23), transforming growth factor β1 (LAPTGF-β1) and transforming 
growth factor A (TGFA). We have also observed that other fat depots including myocardial, epicardial and liver 
fat exhibited similar trend with these growth factor proteins. However, these associations were weaker than those 
of pericardial fat. In addition, we found that there is no significant correlation between TGFA and myocardial, 
epicardial and liver fat or between FGF23 and myocardial and epicardial fat.
We have also observed high correlations between pericardial fat and the levels of various differentiation clus-
ters (CD5, CD6, tumour necrosis factor-related apoptosis-inducing ligand TRAIL, i.e. CD253, and CUB domain 
containing protein 1 CDCP1, i.e. CD318). On the other hand, we found no significant association between 
increasing levels of CD5 and epicardial fat, as well as CD6 and myocardial fat. Among different interleukin 
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families, only IL6, IL8 and IL18R1 were significantly correlated with each fat depot while the highest correlation 
was again observed with pericardial fat. Increasing levels of epicardial, pericardial and liver fat showed significant 
correlations with IL18, whereas levels of IL10 had significant correlations with pericardial and liver fat.
Furthermore, eight different inflammatory chemokines showed a significant positive correlation with at least 
one of the measured ectopic fat depots. Closely-related chemokines such as MIP-1α (CCL3) and MIP-1β (CCL4) 
presented identical trends and very similar relationships with measured ectopic fat depots. MCP1 (CCL2) pre-
sented significant positive association with all measured ectopic fat depots except epicardial fat. CXCL10 was 
found to have significant relationship only with liver and epicardial fat. Chemokines including CCL11, MCP4 
(CCL13) and CCL19 showed significant positive correlations with at least one of the measured ectopic fat depots.
Interestingly, we found that serum levels of other inflammatory proteins including oncostatin (OSM), 
FMS-like tyrosine kinase 3 ligand (FLT3L), tumour necrosis factor superfamily member 14 (TNFSF14), osteo-
protegerin (OPG), glial cell-derived neurotrophic factor (hGDNF), adenosine deaminase (ADA), caspase-8 
(CASP8) and matrix metalloproteinase-1 (MMP-1) presented the strongest positive association with pericardial 
fat. Multi-protein E3 ubiquitin ligase complex (SCF) was the only inflammation factor showing negative correla-
tion with any fat depot (liver fat).
Our analysis indicated that a high ectopic fat level correlates intimately with pro-inflammatory factors/medi-
ators as well as cancer related plasma proteins. In order to investigate the tissue of origin for each secreted pro-
tein, we checked the mRNA expression level of each protein in major human tissues using the data presented in 
Human Protein Atlas19–21, specifically expressed (tissue enriched, tissue enhanced, group enriched) either in liver, 
adipose tissue or heart muscle. Among all genes, 3 are specific to these tissues: FGF21, IL6, and CCL19. FGF21 
exhibited a high correlation with liver fat and is a liver tissue enriched gene. In turn, IL6 is significantly correlated 
Figure 1. Heatmap visualization based on Spearman correlation between variables of interest (column wise) 
and clinical parameters (row wise). Colour key indicates strength of a relationship: blue colour – negative 
relationship, red colour – positive relationship. *Significant relationship after FDR correction and significance 
level of 0.05.
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with pericardial fat and is enhanced to adipose tissue. Finally, CCL19 is significantly correlated with pericardial 
fat and displays enriched expression in adipose tissue among other tissues. In addition, though TNFSF14 and 
CSF1 are found in multiple tissues, their highest expression is observed in adipose tissue (Supplementary Table 2).
Association of lipidome and various fat depots. We then sought to identify significant associations 
between lipid classes and ectopic fat depots and observed significant correlations involving five different lipid 
classes including cholesterol ester (CE), triacylglycerol (TAG), phosphatidylcholine (PC), lysophosphatidylcho-
line (LPC) and sphingomyelin (SM). Altogether, 67 different lipid species were found to be associated with the 
measured ectopic fat depots (Fig. 3). TAGs were the most abundant class in terms of number, with 32 unique 
species significantly correlating with at least one observed ectopic fat. TAGs containing fatty acids (FA) with C48 
to C50 total carbon atoms regardless of saturation showed strong positive correlations with measured ectopic fat 
depots. The exception were TAG (50:4) species which showed negative correlations with ectopic fat depots (liver 
and pericard). TAGs possessing FA with C52 to C58 showed overall negative correlations, with exception of TAGs 
(52:1, 52:2, 54:2) that showed positive correlations with some of the ectopic fat depots. SM was the second most 
abundant class detected in this analysis, and almost 3/4 of species showed positive correlations with ectopic fat 
depots. From the SM pool, diSM (18:0) stands out with the highest positive correlation towards ectopic fat depots. 
Figure 2. Heatmap visualization based on Spearman correlation between variables of interest (column wise) 
and inflammation-associated proteome (row wise). Colour key indicates strength of a relationship: blue colour 
– negative relationship, red colour – positive relationship. *Significant relationship after FDR correction and 
significance level of 0.05.
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Members of different PC species showed both positive and negative associations with measured fat depots. PC 
(C36: and C38:) species presented a shift in correlations with fat depots from positive to negative as the number 
of double bounds increased while, PC (C32:) species showed the opposite behaviour. All CE species but CE (18:2) 
were found to be positively correlated with increasing levels of fat in measured ectopic fat depots. Furthermore, 
CEs (20:3) consistently showed strong correlations with the measured ectopic fat depots. Our analysis showed 
that liver fat had the highest absolute correlation with the changes in the lipidome (Fig. 3).
Metabolome characteristics. To understand the individual role of each metabolite, we performed an 
untargeted metabolomics study using the platform by Metabolon Inc., as previously described22. Metabolome 
screening revealed eight metabolic pathways (amino acid, carbohydrate, cofactor/vitamin, energy, lipid, nucleo-
tide, peptide and xenobiotics) significantly associated with ectopic fat depots. Major pathways were further classi-
fied into 40 different metabolic sub-pathways, exhibiting the magnitude of altered metabolome as a consequence 
of obesity (Fig. 4). Here, correlation analysis revealed both positive and negative association between compounds 
involved in amino acid metabolism and measured ectopic fat. The level of metabolites related to carbohydrate 
metabolism specifically in pathways responsible for metabolism of carbohydrates like glucose, mannose, lac-
tate, pyruvate, aconitate (cis or trans), α-ketoglutarate and succinylcarnitine showed positive correlations with 
accumulation of ectopic fat depots. Compounds related to lipid metabolism were found to be altered markedly 
in terms of numbers (60) and extent of different lipid sub-pathways (16), including phospholipid metabolism 
and sphingolipid metabolism. Glycerophosphoryl cholines (GPC), ethilonamines (GPE) and inositols (GPI) 
Figure 3. Heatmap visualization based on Spearman correlation between variables of interest (column wise) 
and lipidome (row wise). Colour key indicates strength of a relationship: blue color – negative relationship, red 
colour – positive relationship. *Significant relationship after FDR correction and significance level of 0.05.
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were highly correlated with the level of fat in the measured depots. On the other hand, the plasma level of GPC 
(18:1/18:2) and α-GPC were negatively associated with the measured ectopic fat depots.
Besides major changes in some phospholipid sub-pathways, alterations were observed in monoacylglycerol, 
diacylglycerol, endocannabinoid, polyunsaturated fatty acid (n3 and n6), secondary bile acid, and sterol metab-
olites that showed overall positive correlations with the measured ectopic fat depots. FAs and related metabolites 
showed both positive and negative correlations with fat depots, whereas lysolipid, lysoplasmalogen, plasmalogen 
and steroid metabolism showed overall negative associations with minor exceptions (Fig. 4). In addition, metab-
olites in both nucleotide and peptide metabolism showed overall positive correlations with the level of meas-
ured ectopic fat. Overall, the metabolites with the strongest positive correlations across the measured ectopic fat 
depots were glutamate, N-palmitoyl-sphinganine (CER (d18:0/16:0)), glucose, 1-palmitoyl-3-linoleoyl-glycerol 
(16:0/18:2) and 1-stearoyl-2-arachidonoyl-GPI (18:0/20:4).
Identifying the key variables for predicting fat depots. Finally, we sought to identify biomarkers with 
high prediction capabilities for different ectopic fat depots in patients with diagnosed NAFLD using machine 
learning. We used a Random Forest (RF) algorithm for feature selection based on mean decrease of accuracy 
(MDA). This analysis was performed for each variable of interest (myocardial, epicardial, pericardial and liver 
fat) across four different datasets (clinical, inflammation-associated proteome, lipidome and metabolome). Top 
15 variables predicted by the RF (Table 1 – top five, details in Supplementary Table 3), we then evaluated for 
their individual classification ability by estimating AUC (Table 2 – highest AUC score, details in Supplementary 
Table 4). The top five covariates from the ROC analysis across the datasets showed high classification ability 
Figure 4. Heatmap visualization based on Spearman correlation between variables of interest (column wise) 
and metabolome (row wise). Colour key indicates strength of a relationship: blue colour – negative relationship, 
red colour – positive relationship. *Significant relationship after FDR correction and significance level of 0.05.
www.nature.com/scientificreports/
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Myocardial TG Epicardial fat Pericardial fat Liver fat
Clinical Data
LV early diastole Visceral fat Waist Waist
Waist Leptin Visceral fat Fasting insulin
Weight Insulin 1 h Leptin HOMA-index
AFABP AFABP Fasting insulin Visceral fat
BMI Fasting insulin HOMA-index Weight
Inflammation-Associated Proteome
FGF 21 TNFSF 14 HGF CDCP1
LAPTGF-β1 FGF 21 CDCP1 FGF 21
IL 18R1 IL 18R1 TNFSF 14 HGF
HGF HGF TRAIL IL 18R1
CDCP1 IL 6 IL 18R1 IL 6
Lipidome
CE 20:3 CE 20:3 diSM 18:0 TAG 50:1
TAG 56:4 PC 38:3 LPC 18:2 diSM 18:0
PC 38:3 LPC 16:1 PC 38:3 CE 20:3
LPC 18:2 TAG 52:1 LPC 16:0 SM 18:0
CE 16:1 CE 18:0 CE 20:3 TAG 52:1
Metabolome
Glutamate *PE (16:0/18:1) *CER (d18:0/16:0) Glutamate
Glucose *PI (18:0/20:4) Glutamate γ- glutamyl-leucine
*DAG (16:0/18:2) Glutamate Glucose *CER (d18:0/16:0)
*PE (18:0/20:4) *PE (18:0/20:4) *PC (18:0/20:4) *DAG (16:0/18:2)
*PC (16:0/16:1) *SM (d18:2/16:0, d18:1/16:1) *SM (d18:2/16:0, d18:1/16:1) *PE (16:0/18:1)
Table 1. RF results of top 5 most important biomarkers (mean decrease in accuracy). *DAG (16:0/18:2) – 
1-palmitoyl-3-linoleoyl-glycerol (16:0/18:2); *PE (18:0/20:4) – 1-stearoyl-2-arachidonoyl-GPE (18:0/20:4); 
*PC (16:0/16:1) – 1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1); *PE (16:0/18:1) – 1-palmitoyl-2-oleoyl-GPE 
(16:0/18:1); *PI (18:0/20:4) – 1-stearoyl-2-arachidonoyl-GPI (18:0/20:4); ‘SM (d18:2/16:0, d18:1/16:1) – 
sphingomyelin (d18:2/16:0, d18:1/16:1); *CER (d18:0/16:0) – N-palmitoyl-sphinganine (d18:0/16:0); *PC 
(18:0/20:4) – 1-stearoyl-2-arachidonoyl-GPC (18:0/20:4).
Predictors AUC
95% confidence interval
SN SP ThresholdLower limit Upper limit
Myocardial TG
Waist 0.905 0.810 1.000 0.92 0.84 90.5 cm
CDCP1 0.837 0.725 0.949 0.80 0.76 3.31
CE 20:3 0.858 0.748 0.967 0.88 0.80 0.804
Glucose 0.845 0.734 0.955 0.76 0.84 3.5 × 108
Epicardial FAT
Visceral fat 0.952 0.899 1.000 0.92 0.88 1373 mm2
IL - 18R1 0.853 0.748 0.957 0.84 0.80 6.69
CE 20:3 0.888 0.793 0.983 0.92 0.76 0.832
*PE (18:0/20:4) 0.850 0.734 0.965 0.80 0.88 6.5 × 105
Pericardial FAT
Waist 0.975 0.927 1.000 1.00 0.92 93 cm
HGF 0.963 0.919 1.000 0.96 0.88 6.79
diSM 18:0 0.938 0.864 1.000 0.92 0.88 0.225
*CER (d18:0/16:0) 0.942 0.869 1.000 1.00 0.8 8.7 × 105
Liver FAT
Visceral fat 0.984 0.960 1.000 0.92 0.96 1588.5 mm2
CDCP1 0.926 0.844 1.000 0.84 0.96 3.50
diSM 18:0 0.963 0.917 1.000 0.92 0.88 0.226
Glutamate 0.946 0.874 1.000 0.96 0.92 2.9 × 108
Table 2. ROC analysis of potential biomarkers with the highest AUC scores from analysed datasets. Unless 
otherwise stated, all threshold values represent relative units. *PE (18:0/20:4) – 1-stearoyl-2-arachidonoyl-GPE 
(18:0/20:4); *CER (d18:0/16:0) – N-palmitoyl-sphinganine (d18:0/16:0).
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(AUC score 0.80 to 0.98). Of the different heart fat depots, pericardial fat was predicted with the highest classifica-
tion ability across datasets (waist, AUC = 0.98; HGF, AUC = 0.96; diSM 18:0, AUC = 0.94; and CER (d18:0/16:0), 
AUC = 0.94). Considering all the measured ectopic fat depots, liver fat was predicted with the highest classifi-
cation ability across dataset (HOMA-index, AUC = 0.98; diSM 18:0, AUC = 0.96; and glutamate, AUC = 0.95), 
with exception of inflammation-associated proteome (CDCP1, AUC = 0.93). Rather than to compute whether 
differences in AUC between individual covariates are statistically significant, we have combined all covariates 
(Supplementary Table 4, excluding clinical covariates) in a single dataset and evaluated their classification impor-
tance with RF based on MDA (Fig. 5). As the permutation of important covariate greatly affects overall accu-
racy of the RF model, covariates more important for classification will have higher MDA. RF analysis with the 
combined dataset identified several covariate combinations as the most important for classification. Specifically, 
analysis identified four covariates (TAG 50:1, glutamate, diSM 18:0, CE 20:3) in the liver fat classification, five 
covariates (CER (d18.0/16.0), HGF, diSM 18:0, glutamate, TNFSF14) in pericardial fat classification, four covari-
ates (SM (d18:2/16:0, d18:1/16:1), CE 20:3, PC 38:3, TNFSF14) in epicardial fat classification, and four covariates 
(CE 20:3, LAPTGF-β1, glutamate, glucose) in myocardial fat classification (Fig. 5).
Discussion
In this study, we expanded our previous investigation on biomarkers and prediction of myocardial TG content8 
by integrating myocardial, epicardial, pericardial and liver ectopic fat depots with inflammation-associated pro-
teome, lipidome and metabolome. Using single and combined multiple omics data in this cohort of non-diabetic 
men with diagnosed NAFLD, we performed association and classification analyses where we investigated which 
and how markers in the proteome, lipidome, metabolome, as well as their combination, would associate and 
predict fat depot accumulation. For instance, our association analysis showed significantly higher levels of 
well-known risk factors of MetS, T2D and NAFLD, namely AFABP, APOB, HOMA-index, LDL, leptin and TG 
among subjects with elevated levels of the measured ectopic fat depots. Overall, the association and classification 
analyses are highly consistent and show the power of individual markers to classify and discriminate ectopic fat 
depots. Further, in addition to validating known obesity markers, we identified a novel signatures to classify and 
discriminate ectopic fat depots.
Certain biomarkers performed very well in discriminating all measured ectopic fat depots whereas others 
discriminated only specific ones. Individually, visceral fat, HGF, IL-18R1, TNFSF14, CE20:3 and glutamate 
ranked among the top five in discriminating all of the measured ectopic fat depots while waist, fasting insulin 
and HOMA-index, CDCP1, LPC 18:2, PC38:3, diSM 18:0 and CER (d18:0/16:0) ranked in top five discrimi-
nating at least three ectopic fat depots. In addition, we have used a combined dataset of individual biomarkers 
to identify plasma metabolic profiles comprised of biomarkers that robustly classified ectopic fat depots. Our 
analysis revealed several lipid species, inflammation related proteins and single amino acid as a metabolic sig-
nature of measured ectopic fat depots. For instance, the liver fat depot is marked mainly with different lipid 
species (TAG50:1, diSM18:0, and CE20:3) and glutamate, while the metabolic signature of pericardial fat depot is 
mainly presented by elevated levels of CER (d18:0/16:0), diSM18:0, glutamate, HGF and TNFSF14. Furthermore, 
we showed that the metabolic signature of epicardial fat depot is characterized with augmented levels of SM 
Figure 5. RF analysis (combined dataset) – variable importance based on mean decrease in accuracy for liver, 
pericardial, epicardial and myocardial fat.
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(d18:2/16:0, d18:1/16:1), CE20:3, PC38:3 and TNFSF14, while the metabolic signature of myocardial fat depot is 
mainly composed with changes in CE20:3, LAPTGF-β1, glutamate and glucose.
Adiponectin, a highly expressed cytokine by the adipose tissue20, with known anti-atherogenic, anti-diabetic 
and anti-inflammatory properties23, showed significantly reduced serum levels among the subjects with ele-
vated levels of measured ectopic fat depots. This is in agreement with previous obesity related studies reporting 
decreased serum levels of adiponectin among overweighed subjects24. Moreover, our study showed strong inverse 
associations between PFR or LVEDV and ectopic fat depots. Together with the observed positive association of 
systolic and diastolic blood pressures and ectopic fat depot levels, our data suggests that functional and structural 
deterioration of the heart follows accumulation of ectopic fat, as reported previously25,26.
It is well known that the adipose tissue is not only an energy storage but rather a complex and highly active 
metabolic and endocrine organ. Thus, serum concentration of inflammation-related proteins can reflect the pro-
files of measured ectopic fat depots, and serve as potentially good classifiers27. Accordingly, our association analy-
sis highlighted a strong relationship between several growth factors, clusters of differentiation and inflammatory 
cytokines/chemokines and the levels of ectopic fat depots. Among these FGF21, IL-6, CCL19, TNFSF14 and CSF1 
were of particular interest due to their high specificity in liver, adipose tissue or cardiac muscle.
FGF21 is expressed in the liver and plays an important role in regulating lipid and glucose metabolism. Several 
studies have shown that FGF21 overexpression in rodents is associated with weight loss and lower obesity, as well 
as insulin sensitivity in its target tissues20,28,29. However, the metabolic role of FGF21 in humans is not completely 
clear. Human studies have reported a positive association of FGF21 serum levels with obesity and ectopic fat 
depots30–33, which is in agreement with our observations, as well as great variability in FGF21 serum levels34,35. 
Our classification analysis highlighted FGF21 as a good individual classifier of measured ectopic fat depots, but 
not as valuable component of their metabolic signatures.
IL6 expression in adipose tissue, its positive association with obesity, systemic IR and inflammation is in agree-
ment with our observations20,36–38, but its role in obesity and chronic low-grade inflammation is poorly under-
stood. It had been observed that IL6 exhibits dual effect: during acute inflammation, IL6 plays a protective role by 
controlling the expression levels of other pro-inflammatory cytokines. However, IL6 becomes pro-inflammatory 
under chronic inflammation by promoting B-cell differentiation and T-cell activation39–41. Here, IL6 performed 
well as an individual classifier, discriminating all measured ectopic fat depots, but poor in representing their 
metabolic signatures.
CCL19 is a chemokine expressed in adipose tissues that is believed to play an important role in low-grade 
inflammation observed in obesity by recruiting macrophages to those tissues20,42. Animal models showed associ-
ations of the CCL19-CCR7 pathway with obesity-associated inflammation and IR43. Despite these observations, 
CCL19 ranked low for discriminating measured ectopic fat depots.
TNFSF14 is a member of the TNF superfamily, expressed in various human tissues including adipose20,44. 
TNFSF14/HVEM (herpesvirus entry mediator) are involved in obesity-induced inflammation by recruiting 
and enhancing macrophage lineage in adipose tissue, thus subsequently responsible for the release of several 
pro-inflammatory cytokines including TNFα, IL6 and MCP-145. Accordingly, significantly changed serum levels 
of TNFSF14 have been observed among obese subjects44 which is in agreement with our observation. Here, our 
discrimination analysis highlighted TNFSF14 as an excellent individual classifier of pericardial fat, good classifier 
of epicardial and liver fat, and moderate classifier of myocardial fat. In addition, it was found as a valuable meta-
bolic signature component of pericardial and epicardial fat.
CSF1 is a cytokine expressed in a variety of tissues including adipose20. Studies in human and animal models 
proposed a role of CSF1 in proliferation, differentiation and macrophage survival once recruited into adipose 
tissue. Most of the recruited macrophages present in the adipose tissue of obese subjects exhibit high expres-
sion of inflammatory factors, and the macrophage number shows strong positive association with adiposity46. 
Accordingly, CSF1 expression is upregulated in growing adipose tissue47. Though our observations confirmed a 
positive association with obesity, CSF1 did not perform well in discriminating ectopic fat depots.
Metabolic disturbance including amino acid, carbohydrate and lipid metabolism are linked with central and 
peripheral obesity48. Although the underlying pathways are not well understood, recent studies offered new 
insights into the aetiology and relationship between metabolic perturbations and obesity49–51. Here, we showed an 
association between several compounds associated with amino acid metabolism and measured ectopic fat depots, 
among which glutamate presented the strongest association. Moreover, we observed that this is the only com-
pound associated with amino acid metabolism that displays high predictability of measured ectopic fat depots, 
and to be part of their metabolic signatures (excluding epicardial fat). Indeed, obese individuals show increased 
plasma glutamate levels49,52.
Carbohydrate metabolism is altered in obese individuals, who show increased levels of glucose, pyruvate 
and lactate and most of their intermediates. The proposed causes leading to increased plasma glucose levels 
among obese individuals are the global adiposity, increased IR and reduced ability of adipose tissue to store 
glucose49,53. Pyruvate, metabolite important in both carbohydrate and BCAA catabolism was also reported to 
be increased among obese individuals. Pyruvate is converted to lactate, the major precursor of gluconeogenesis 
during anaerobic glycolysis which is upregulated among obese individuals. Indeed, lactate levels were found to 
be increased among obese individuals thus considered as an obesity-related metabolite50,54. In line with the obvi-
ous links between carbohydrate metabolism and obesity, we observed that the majority of metabolites related to 
carbohydrate metabolism had a positive association with measured ectopic fat depots. However, glucose was the 
only metabolite presenting significant associations with all ectopic fat depots. Moreover, our analyses highlighted 
glucose as a good individual classifier of measured ectopic fat depots (excluding epicardial fat), and metabolic 
signature component of myocardial fat.
Plasma lipidome has been extensively used to study association between circulating lipid species and obesity, 
due to the fact that excess body fat may lead to lipotoxicity in tissues other than adipose55. Accordingly, lipid 
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abnormalities of CE, TAG, PC, LPC and SM species are often observed among obese individuals, though the 
behaviour of these species remains unclear and often contradictory49,56. For instance, in a study with weight dis-
cordant monozygotic twins, authors observed an association between obesity and increased levels of SM and LPC 
species and decreased levels of ether-phospholipids57. However, others observed a significant association between 
central obesity, lower LPCs but higher PC and SM levels in young adults58. Here, we observed that all analysed 
lipid classes including CE, TAG, PC, LPC and SM exhibit changes in obesity. Both SMs and ceramides are part of 
sphingolipid family, and as such recognized as structural components of cellular membranes and engaged in sev-
eral biological functions, including cell-to-cell recognition and signalling59,60. Thus, disturbance of sphingolipid 
metabolism may promote cellular stress, mitochondrial dysfunction and insulin signalling. Hanamatsu et al.59 
observed significantly increased serum levels of SM (C18:0 and 24:0) in obese individuals, together with a signif-
icant correlations between SM (C18:0, 20:0, 22:0 and 24:0) and IR, NAFLD and dyslipidaemia. The authors have 
not observed changes in ceramide levels, which may be due to the absence of severe inflammation among obese 
participants. In turn, Luukkonen et al.61 reported significant increases in all analysed ceramides in patients with 
NAFLD, whereas Turpin et al.62 observed elevated expression of C16 ceramide in visceral fat of obese individuals 
as well as strong correlation with BMI and IR. Consistently, ceramide synthase 6-deficient mice were protected 
against obesity, IR and adipose tissue inflammation. In line with these results, our analyses showed a positive 
correlation of SM 18:0 and diSM 18:0 with ectopic fat depots. Furthermore, diSM18:0, CER (d18:0/16:0) and SM 
(d18:2/16:0, d18:1/16:1) were highlighted as good individual classifiers and metabolic signature components of 
specific ectopic fat depots.
LPC is a highly abundant signalling molecule involved in different biological processes such as cellular prolif-
eration, tumour cell invasion and inflammation63. Among the most abundant LPC species we observed a positive 
association between plasma levels of LPC 16:0, 18:0 and measured ectopic fat depots whereas LPC 18:1, 18:2 
showed negative associations. Our classification analysis highlighted LPC 18:2 as a valuable individual classifier 
of ectopic fat depots, consistent with the observed depletion of this species in obese individuals and with the 
negative association with liver fat64–66. However, LPC 18:2 was not considered as a valuable metabolic signature 
component of ectopic fat depots.
Total TAG and cholesterol were previously shown to be increased but very heterogeneous among obese indi-
viduals. Rhee et al.67 observed that more saturated and shorter TAGs exhibit positive associations with IR, but not 
associations with longer TAGs. We have also observed a positive association between shorter TAGs and ectopic 
fat depots, but also negative associations with longer TAGs. Tonks et al.68 observed that several plasma lipids 
including DAGs, LPCs, CEs and TAG are associated with IR, where CE (16:1, 20:4) are in line with our observa-
tions. Furthermore, our analyses highlighted TAG50:1 and CE20:3 as a part of metabolic signatures of one and 
several measured ectopic fat depots, respectively.
Overall, metabolites from lipid metabolism (CE20:3, TAG50:1, PC38:3, LPC18:2, diSM18:0, CER (d18:0/16:0) 
and SM (d18:2/16:0, d18:1/16:1)) were shown to be of great value either as individual predictors or as metabolic 
signature components of specific ectopic fat depots.
Conclusion
NAFLD is a multi-systemic disease caused by excessive fat accumulation in the liver, leading to impairment of this 
tissue. Unfortunately, fat accumulation is not limited only to liver, rather it is affecting extra-hepatic organs and 
quality of life in diagnosed individuals. Here we have used omics data together with computational approaches 
including machine learning, to identify several novel individual non-invasive biomarkers that accurately distin-
guish groups with high and low levels of myocardial, epicardial, pericardial, and liver fat depots. Most impor-
tantly, a combination of omics data highlighted novel fat depot-specific metabolic signatures. However, the 
cross-sectional nature of the study design limits inferences of causality.
Materials and Methods
Ethical approval. The study was approved by the Helsinki University Central Hospital Ethics Committee 
and conforms to the principles outlined in the Declaration of Helsinki. Each subject provided written informed 
consent.
Study population. A total of 75 men were examined using the same study cohort as have been previously 
described11. Thirty-seven patients fulfilled the criteria for the metabolic syndrome69. In these participants, myo-
cardial ischemia was excluded by means of adenosine stress MR perfusion test.
Exclusion criteria from the study included the following: other known acute or chronic disease based on med-
ical history, physical examination, and standard laboratory tests (blood counts, creatinine, aspartate aminotrans-
ferase, alanine aminotransferase, thyroid-stimulating hormone), T2D (based on a 2-h oral glucose tolerance test), 
significant alcohol consumption (more than 20 grams per day), and treatment with other lipid lowering therapy 
than statins. As the hormonal status and use of contraceptives modify lipid metabolism in women, only male 
subjects were recruited. Smoking and elevated liver enzymes were allowed. Five study subjects were on regular 
medication for hypertension, three for dyslipidemia (statins), and one for both hypertension and dyslipidemia.
Demographic variables and biochemical investigations. Body mass index (BMI) was calculated by 
dividing weight in kilograms by the square of the height in meters (kg/m2). Waist circumference was measured at 
a level midway between the lower rib lateral margin and the iliac crest in the horizontal position. Blood pressure 
was recorded as an average of five measurements obtained in the sitting position after a 5 min rest using a BPM-
200 monitor (Quick Medical, WA, USA). The subjects were classified as present, past, or non-smokers.
Blood samples were collected after an overnight fast. Total serum cholesterol, TGs, and high-density lipo-
protein cholesterol were measured by Konelab analyzer 60i with Konelab TM kits (both from Thermo Fisher 
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Scientific, Finland). The concentration of low-density lipoprotein cholesterol was calculated by the Friedewald 
formula70. Fasting and postload glucose were assessed by the hexokinase method (Gluco-quant, Roche 
Diagnostics, Basel, Switzerland) using either a Hitachi 917 or Modular analyzer (both from Hitachi Ltd, Tokyo, 
Japan). Serum insulin concentration was determined by double-antibody radioimmunoassay (Pharmacia RIA 
kit, Pharmacia, Uppsala, Sweden). The insulin-resistance homeostasis model assessment (HOMA) index was 
calculated by using the formula: (fasting plasma glucose × fasting plasma insulin)/22.571.
Quantification of myocardial TG content. For measuring the myocardial TG content, cardiac 1H-MRS 
was performed in a 1.5 T MR imager (Magnetom Avanto; Siemens AG, Erlangen, Germany) using a standard 
flex-coil for signal reception. The spectroscopic volume of interest was placed within the interventricular septum 
using the end-systolic cardiac cine images in three planes. The localizer images and spectroscopic data acquisition 
were double-triggered to end-exhalation and end-systole, using Prospective Acquisition Correction navigator 
echoes (PACE, WIP-sequence, program version B17) to control for respiratory movement and ECG-derived R 
wave to control for cardiac pulsation. Spectral localization and data collection were performed with the PRESS 
sequence with 35 ms echo time, while repetition time (TR > 3000 ms) did not fall below the respiratory cycle 
length. Navigator echoes were collected from the lung-diaphragm interface and the end-systole triggering was 
set at about 80% of the resting heart rate of the subject. The spectra were collected with and without water sup-
pression, using 32 and 4 acquisitions, respectively, and analyzed with jMRUI v3.0 software using the AMARES 
algorithm72 to determine water (4.7 ppm), methylene (1.3 ppm) and methyl (0.9 ppm) resonance areas. The myo-
cardial TG content was expressed as a ratio of fat to water (%). Correction for methylene T2 relaxation was not 
possible due to lack of reliable data for cardiac application.
Quantification of epicardial and pericardial fat. The 4-chamber oriented cine images were applied 
for measuring the epicardial and pericardial adipose tissue area as described previously11. All phases of the cine 
images were inspected and the measurements were performed in the end diastolic image using a standard radio-
logic workstation (Impax 5.5 software, Agfa Healthcare, Mortsel, Belgium). The areas of high intensity fat layers 
between the myocardium and the visceral pericardium (epicardial fat) and outside the parietal pericardium (per-
icardial fat) were measured.
Quantification of hepatic and abdominal fat depots by MRI and 1H-MRS. For measuring hepatic 
TG content, 1H-MRS was performed in a 1.5 T MR imager (Magnetom Avanto; Siemens AG, Erlangen, Germany). 
Distribution of visceral and subcutaneous adipose tissue were measured as previously described11,18.
Analysis of inflammation-associated proteome, lipidome and metabolome. Untargeted metab-
olomics profiling of plasma was performed by Metabolon Inc., as previously described22. Samples were prepared 
using the automated MicroLab STAR system from Hamilton Company. In brief, sample preparation was con-
ducted using aqueous methanol extraction process to remove the protein fraction while allowing maximum 
recovery of small molecules. The resulting extract was divided into four fractions: one for analysis by UPLC/MS/
MS (positive mode), one for UPLC/MS/MS (negative mode), one for GC/MS, and one for backup. Samples were 
placed briefly on a TurboVap (Zymark) to remove the organic solvent. Each sample was then frozen and dried 
under vacuum.
Samples were then prepared for the appropriate instrument (either UPLC/MS/MS or GC/MS). Inflammatory 
protein biomarkers were analyzed using the Proseek Multiplex Inflammation I96×96 array (Olink Bioscience, 
Uppsala, Sweden).
For lipidomics, plasma was extracted using butanol/methanol (BUME) as previously described73. Internal 
standards (either deuterated or containing heptadecanoyl (C17:0) fatty acids) were added during the extraction. 
Analysis of CE, TG, PC, LPC and SM were made using direct infusion on a QTRAP 5500 mass spectrome-
ter (Sciex, Concord, Canada) equipped with a robotic nanoflow ion source, the TriVersa NanoMate (Advion 
BioSciences, Ithaca, NJ). Detection of cholesteryl esters was made using precursor ion scanning in positive mode 
using m/z 369 (protonated cholestadiene) as fragment ion74. Detection of TG was made using neutral loss scan-
ning in positive mode75. Phospholipids were analysed in both positive and negative ion mode using (multiple) 
precursor ion scanning76,77. After alkaline hydrolysis in 0.1 M potassium hydroxide in methanol, sphingomyelin 
was analysed in positive mode using m/z 184 (phosphocholine) as fragment ion. Quantification of lipids was 
made using a one point calibration against the added, lipid class specific, internal standard. Data was evaluated 
using LipidView software.
Statistical analyses. All statistical analyses were conducted in R 3.2.1 for Mac (R Development Core Team, 
2015). Categorical variables of myocardial, epicardial, pericardial and liver fat were defined using 33% of high 
and low values. All continuous variables with more than 5% of missing values were excluded from the analysis. 
Continuous variables were analysed for the normality with Shapiro-Wilk normality test and Leven’s test was used 
to assess the groups equality of variances (data not shown). Between group differences (high = 25; low = 25) 
were examined using Mann-Whitney U test (i.e. Wilcoxon Rank-Sum test). In order to assess the relationship 
between continuous variables Spearman correlation factor was calculated. Classification analysis/variable selec-
tion was conducted using random forest (RF) machine learning algorithm. RF modelling is appealing technique 
for high-dimensional data, shown to identify important covariates with respect to the variable of interest. Even 
though RF can be run with default settings it is common by the users to tune certain parameters in order to obtain 
more stable and reproducible model. For the same reason the number of growing trees was set to 100,000 while all 
other parameters were left unchanged78. RF algorithm is constructing each tree from the new training set, drawn 
with replacement from the original data. About one-third of the training set are left out and used as a test set (i.e. 
out of bag, OOB) upon which unbiased estimate of classification error rate is calculated. The study conducted 
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by Breiman79 presented empirical evidence that OOB estimate of classification error is as accurate as using an 
independent test set thus, removing the need for the same. A detailed description of the RF algorithm and its 
optimization can be found elsewhere80. Area under the Receiver Operating Characteristic (ROC) curves (AUC) 
were used to estimate the diagnosis ability of individual biomarkers obtained from RF as a classifier in a clinical 
application. An optimal criterion was defined for each potential biomarker by maximizing both true positive (i.e. 
sensitivity, SN) and true negative (i.e. specificity, SP) rates, where higher AUC indicate better classifications78,81. 
All P-values are reported after FDR correction (Benjamin-Hochberg) with significance level of 0.05.
Data Availability Statement
The data that supports the findings of this study are available from the corresponding author upon request.
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